Clinical Research Directory
Browse clinical research sites, groups, and studies.
Vaginal Prasterone Versus Estriol in Women With Pelvic Floor Disorders
Sponsor: Poznan University of Medical Sciences
Summary
This prospective, non-randomized comparative study evaluated the effects of short-term vaginal treatment with prasterone or estriol in women with pelvic floor disorders who were awaiting urogynecological surgery. A total of 74 women were included, with 37 participants receiving vaginal prasterone and 37 receiving vaginal estriol. Treatment was administered before surgery for approximately 8 weeks. The study assessed changes in pelvic floor symptoms and quality of life using the WHOQOL-BREF questionnaire and symptom severity scales. The aim was to compare the effects of the two vaginal treatments on symptoms and quality of life before urogynecological surgery.
Official title: Short-Term Vaginal Estriol Versus Prasterone in Women With Pelvic Floor Disorders: A Prospective Non-Randomized Comparative Study of Symptoms and Quality of Life"
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
74
Start Date
2022-10-01
Completion Date
2026-01-31
Last Updated
2026-10-08
Healthy Volunteers
No
Interventions
Prasterone (DHEA)
6.5 mg vaginally once daily for 8 weeks before urogynecological surgery.
Estriol
Vaginal estriol (Oekolp forte) was administered once daily for 14 days, followed by twice-weekly administration for 8 weeks before urogynecological surgery. In participants with advanced pelvic organ prolapse, estriol cream was used when clinically indicated.
Locations (1)
Gynecology and Obstetrics Clinical Hospital, Poznan University of Medical Sciences
Poznan, Greater Poland Voivodeship, Poland